Pharmadule, a Sweden-based company specialising in design and construction of modular pharmaceutical facilities and process equipment, has partnered with WuXi XDC.
WuXi XDC is a China-based Contract Research, Development, and Manufacturing Organisation (CRDMO) that specialises in antibody-drug conjugates (ADCs) and the bioconjugate market.
Pharmadule is a Morimatsu Group company that in addition to modular facilities, manufactures and supplies process equipment to a variety of industries.
The new partnership has led to the successful delivery of state-of-the-art modular production facilities, including the first batch of nearly 100 modules, to WuXi XDC's Singapore manufacturing site.
This marks a key milestone in the partnership, representing significant progress and advancing both companies’ goals in biopharmaceutical innovation.
The partnership has led to the successful delivery of state-of-the-art modular production facilities, including the first batch of nearly 100 modules
The new Singapore facility
WuXi XDC’s Singapore manufacturing facility, located in Tuas Biomedical Park, incorporates the world’s leading integrated design concept for ADC/XDC drug production.
The main plant, comprising over 200 modules supplied by Pharmadule Morimatsu, will enable seamless production of drug substances (DS) and drug products (DP) at clinical and commercial scales.
The facility is also equipped with quality control (QC) laboratories, Manufacturing Science and Technology (MSAT) innovation labs, warehousing, and other essential support functions.
Designed with process flexibility at its core, this state-of-the-art facility features a world-class multi-product manufacturing line, capable of meeting the full spectrum of ADC/XDC drug development and manufacturing requirements. WuXi XDC’s Singapore site is on track to be operational by late 2025.
The facility is also equipped with quality control (QC) laboratories
One of the key challenges in ADC/XDC manufacturing is preventing cross-contamination while maintaining high safety standards.
To address this, the facility employs special design to ensure the high quality of each batch of product and the safety of operators, meeting the stringent requirements for the production of ADCs and XDCs.
Dr Jimmy Li, CEO of WuXi XDC, said: "The successful shipment of this modular facility marks a significant step forward in our collaboration with Pharmadule Morimatsu, reflecting our broader vision of addressing the increasing global demand for ADC and bioconjugate therapies. It highlights our commitment to expanding world-class manufacturing capabilities while advancing our dual-sourcing strategy, ensuring our global clients have scalable access to high-quality manufacturing solutions."
Daoquan Li, CEO of Morimatsu Pharmadule, China branch, said: "Leveraging our extensive experience in global modular facility delivery, we proudly support the development of WuXi XDC’s advanced ADC manufacturing facility in Singapore."
"The modular design enhances both productivity and flexibility, enabling WuXi XDC to further expand its global manufacturing capabilities," Daoquan Li explained. "We are committed to continuing our support of WuXi XDC in advancing the construction of its Singapore site, and to collaborating further in contributing to the growth of the biopharmaceutical industry."